9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
- Vurolenatide's half-life is consistent with twice-monthly dosing -- Top-line results from the ongoing Phase 2 VIBRANT trial on track...
Scott Leune Names 2026 Sponsors Selected to Support Dental Practice Growth and Operations